Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis

Xuni He, Zhuhua Dai, Peina Shi, and Jiemin Hong

Gastroenterology Department, Ningbo Yinzhou No. 2 Hospital, No. 998, Qianhe Road, Yinzhou District, Ningbo City, Zhejiang Province 315199, China

Correspondence should be addressed to Jiemin Hong; hongjiemin0913@163.com

Received 10 September 2021; Accepted 30 September 2021; Published 13 October 2021

Academic Editor: Songwen Tan

Copyright © 2021 Xuni He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis.

Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0h–24h, 24h–48h, and >48h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48h after treatment.

Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group (P < 0.01). The proportion of patients with excellent response was notably higher in the study group than in the control group (P < 0.05). The overall response rate of the study group was 90.48%, which was significantly higher than 71.43% in the control group (P < 0.05). The study group had lower transfusion volume of red blood cells, shorter hemostatic time, and lower rebleeding rates than the control group (P < 0.01). The hemostatic rate of 0 h–24 h in the study group was remarkably higher than that in the control group (P < 0.05). The hemostatic rate of >48 h in the study group was lower than that in the control group (P < 0.05). The overall incidence rate of complications in the study group was 9.52%, which was significantly lower than 30.95% in the control group (P < 0.05).

Conclusion. These data suggest that intravenous drip of somatostatin followed by restricted fluid resuscitation leads to a better clinical efficacy in treating upper gastrointestinal bleeding in patients with liver cirrhosis considering higher resuscitation rate and hemostatic rate and reduced incidence of complications, which is conducive to the recovery of patients and worthy of further clinical promotion.

1. Introduction

Liver cirrhosis is one of the common severe diseases, which is mainly caused by connective tissue hyperplasia and nodular regeneration caused by diffuse liver injury. Clinical decompensation of liver cirrhosis is characterized by abdominal dropsy, sepsis, variceal bleeding, encephalopathy, and nonobstructive jaundice [1], which seriously affect the patient’s life and health. Liver cirrhosis has been considered as an advanced liver disease that eventually leads to death in the absence of liver transplantation [2]. In developed countries, liver cirrhosis is the cause of increased incidence rate and mortality rate. It is regarded as the fourteenth most common cause of death in the world, but ranked fourth in central Europe. According to different stages of disease, the one-year mortality of liver cirrhosis varies from 1% to 57% [3].

At the end stage of disease, upper gastrointestinal bleeding is one of the most common complications of liver cirrhosis, which is mainly induced by esophageal and gastric...
varices and rupture of gastric varices [4]. Upper gastrointestinal bleeding is located near the Treitz ligament, with the mortality of 6%–10% [5]. It has been reported that the mortality of liver cirrhosis complicated with upper gastrointestinal bleeding exceeds 40.0%, which poses a great threat to the life and safety of patients [1]. Therefore, it is of great clinical significance to take early preventive and therapeutic measures to reduce the mortality. The treatment medicines such as nonselective β-receptor blockers, statins, oral antibiotics, and anticoagulants have been used in various combinations to prevent and treat complications of liver cirrhosis [6, 7]. Somatostatin and its analogues are a peptide hormone containing 14 amino acids isolated from the hypothalamus. It can increase the sensitivity of visceral vessels to vasoconstrictors, reduce portal vein pressure, block vasodilation, and promote visceral vasoconstriction [8]. Fluid resuscitation with colloidal and crystalline solutions is an effective method and a common intervention in acute medicine. Clinically, the selection of resuscitation fluid depends on physiological principles but largely varies from clinician to clinician [9]. It is the basis of nursing care for patients with sepsis, hemorrhagic shock, and other life-threatening diseases [10]. Restricted fluid resuscitation mainly refers to controlling the fluid input speed to ensure that the patient’s blood pressure is maintained at a low and stable level, improve the body’s self-protective compensation function, and finally achieve the best and maximum oxygenation and volume expansion with the minimum total amount of fluid [11].

Numerous studies have been conducted on the somatostatin alone for the treatment of bleeding in liver cirrhosis [12], esophageal varices [13], and upper gastrointestinal bleeding [14]. However, few studies have been found on the combination of somatostatin and fluid resuscitation in the treatment of liver cirrhosis and upper gastrointestinal bleeding. In this study, the application of somatostatin combined with restricted fluid resuscitation to 42 liver cirrhosis patients with upper gastrointestinal bleeding was analyzed, which might provide a theoretical basis for clinical treatment.

2. Materials and Methods

2.1. Study Design. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. All patients were examined by liver function tests and transabdominal ultrasound, fulfilling the guidelines for the prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. All patients presented gastrointestinal bleeding symptoms such as hematemesis and black stool 24 hours before admission, with a blood volume of more than 1000 ml, accompanied by varying degrees of hemoglobin reduction and blood pressure reduction. These 84 patients were randomly assigned into the study group (n = 42) and control group (n = 42). This study has been approved by the Ethics Committee of Ningbo Yinzhou No. 2 Hospital.

2.2. Inclusion and Exclusion Criteria. All participants were diagnosed with liver cirrhosis and upper gastrointestinal bleeding through a variety of examinations, such as blood routine, gastroscopy, selective arteriography, CT, MRI, and color Doppler ultrasound. All patients and their families agreed to participate in the study, with a high degree of cooperation, with complete clinical data. Those who had any of the following conditions were excluded: administration of nonsteroidal, acid-inhibitory and anti-inflammatory drugs; severe organic diseases such as respiratory failure, heart failure, and cerebral infarction; upper gastrointestinal bleeding caused by noncirrhotic factors, such as gastrointestinal surgery and peptic ulcer; infectious disease; primary liver cancer; intolerance to gastroscopy; and mental or cognitive impairment.

2.3. Treatment Protocols. After admission, the two groups received regular care involving but not limited to fasting for 3 days, liver protection, antihypertensive drugs to portal vein, inhibition of gastric acid, and anti-infection. Blood transfusion was carried out on the patients if necessary. In the meantime, the vital signs of the patients were closely observed, and urination and defecation were recorded within 24 hours. The control group was given intravenous infusion of somatostatin (specification: 3 mg, National Permission No. H20066708, Yangzi River Pharmaceutical Group Co., Ltd., CN). First, somatostatin with 0.250 mg as the loading dose was intravenously injected into the patients, and then intravenous drip was performed immediately at the speed of 0.250 mg/h. The usage dose of somatostatin could be added to 0.375 mg/h or 0.500 mg/h according to the treatment needs of the patients. Somatostatin injection and restricted fluid resuscitation. In general, glucose injection was taken as main fluid and sodium injection was avoided except levofoxacin injection. The total volume of infusion was controlled within 1000 ml/24 h (not including blood transfusion: the maximum amount ≤400 ml/24 h). The infusion speed was controlled under 20–40 drops/min. The patients without obvious shock received infusion at the speed of 20 drops/min. Those patients with lower systolic blood pressure (<80 mmHg) received infusion at a higher dropping speed. However, the maximum dropping speed shall be controlled at ≤40 drops/min. During this period, the central venous pressure, arterial pressure, and urine volume of the patients should be closely observed.

2.4. Main Outcome Measures. All study participants were examined 48 h after treatment for their hemoglobin (Hb) (g/L), platelet (×10⁹/L), fibrinogen (g/L), and hematocrit (L/L). The transfusion volume of red blood cells (RBC), hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications including hepatic encephalopathy, ascites, spontaneous peritonitis, hepatorenal syndrome, and hydrothorax were compared between the two groups.
Hemostasis was used to reflect clinical efficacy and classified into excellent, good, and nonresponse: excellent response, the absence of hematemesis and gastrointestinal reactions including hematemesis and hematochezia, stable or increased Hb levels, stable blood pressure and heart rate, and clear or colorless gastric tube drainage fluids within 48 h after treatment; good response, the absence of hematemesis and gastrointestinal reactions, stable Hb levels, blood pressure, and heart rate, and clear or colorless gastric tube drainage fluids within 72 h after treatment; nonresponse, continues hematemesis and hematochezia, red and ker-
mesinus gastric tube drainage fluids, continues reduction of Hb levels and blood pressure, and increased heart rate within 72 h after treatment. Overall response rate = (excellent response + good response)/cases × 100%.

2.5. Statistical Analysis. All data were processed by SPSS23.0 statistical software. The measurement data were expressed as a manner of mean ± standard deviation and compared using the t-test. The counting data were described by rate or ratio and compared using the chi-square test. $P < 0.05$ indicated the difference was statistically significant.

3. Results

3.1. Baseline Characteristics of Study Participants. The study group encompassed 26 males and 16 females, with an average age of 49.13 ± 8.23 years. According to Child–Pugh class of liver function, there were 3 cases evaluated as A class, 25 cases as B class, and 14 cases as C class (28 cases of hepatitis B-induced liver cirrhosis and 14 cases of alcoholic cirrhosis; 17 cases with gastric varices and 25 cases without). The control group included 29 males and 13 females, with an average age of 43.32 ± 8.21 years, and there were 2 cases of Child–Pugh A class, 27 cases of Child–Pugh B class, and 13 cases of Child–Pugh C class (26 cases of hepatitis B-induced liver cirrhosis and 16 cases of alcoholic cirrhosis; 20 cases with gastric varices and 22 cases without). These data between the two groups revealed no significant difference on age, gender, Child–Pugh class of liver function, causes of liver cirrhosis, and the presence of gastric varices ($P > 0.05$).

3.2. Clinical Efficacy of Intravenous Drip of Somatostatin Alone or Followed by Restricted Fluid Resuscitation. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment ($P < 0.01$; Table 1). After treatment, the clinical efficacy of the two groups was improved. Excellent response was found in 28 patients, good response was found in 10 patients, and nonresponse was found in 4 patients in the study group. Excellent response was found in 18 patients, good response was found in 16 patients, and nonresponse was found in 8 patients in the control group. The proportion of patients with excellent response was notably higher in the study group than in the control group ($P < 0.05$). The proportions of patients with good response and nonresponse did not differ between the two groups. The overall response rate of the study group was 90.48%, which was significantly higher than 71.43% in the control group ($P < 0.05$; Table 2). There were 9 nonresponders in the control group, among which 5 cases were given endoscopic treatments, 2 cases were given surgical treatments, and 1 case died of hemorrhagic shock. There were 4 nonresponders in the study group, among which 3 cases were given endoscopic treatments, 1 case was given surgical treatments, and none died of hemorrhagic shock.

3.3. High Resuscitation Rate after Intravenous Drip of Somatostatin Alone or Followed by Restricted Fluid Resuscitation. As listed in Table 3, the resuscitation rate in the study group and the control group was 90.00% and 82.60%, respectively ($P > 0.05$). The infusion volume in the study group was significantly less than that in the control group ($P < 0.05$).

3.4. High Hemostatic Rate within 24 h after Intravenous Drip of Somatostatin Alone or Followed by Restricted Fluid Resuscitation. As shown in Table 4, the study group had lower transfusion volume of red blood cells, shorter hemostatic time, and lower rebleeding rates than the control group ($P < 0.01$). During the time of 0h–24 h, 24h–48 h, and >48 h, the cases, who succeeded in hemostasis, in the study group were 24 (57.14%), 13 (30.95%), and 5 (11.90%), respectively, and the cases in the control group were 15 (35.71%), 12 (28.57%), and 15 (35.71%), respectively. The hemostatic rate of 0h–24 h in the study group was remarkably higher than that in the control group ($P < 0.05$). There was little difference between the hemostatic rate of 24h–48 h in the study group and the control group ($P > 0.05$). The hemostasis rate of >48 h in the study group was lower than that in the control group ($P < 0.05$).

3.5. Intravenous Drip of Somatostatin Alone or Followed by Restricted Fluid Resuscitation Reduced the Incidence of Complications. After treatment, the patients in the two groups experienced different complications, such as hepatic encephalopathy, ascites, spontaneous peritonitis, hepatorenal syndrome, and hydrothorax. The overall incidence rate of complications in the study group was 9.52%, which was significantly lower than 30.95% in the control group ($P < 0.05$; Table 5).

4. Discussion

Liver cirrhosis is regarded as an advanced chronic liver disease with many complications, of which upper gastro-
intestinal bleeding is one of the most common acute and critical diseases [15]. Upper gastrointestinal bleeding is usually defined as bleeding near the Treitz ligament. It involves variceal and nonvariceal types. Variceal upper gastro-
testinal bleeding is most frequently caused by gastroesophageal varices and isolated gastric varices. Non-
variceal upper gastrointestinal bleeding is caused by a series of factors, such as peptic ulcer, gastroduodenal erosion, erosive esophagitis, arteriovenous malformations, and upper
gastrointestinal tumors [16, 17]. The main clinical manifestations of upper gastrointestinal bleeding are hematemesis (bright red emesis or coffee-ground emesis), hematochezia, hemorrhagic shock, and hemodynamic disorder. It might develop secondary symptoms, such as syncopation attacks, fatigue, and weakness. In severe cases, it will lead to acute peripheral circulation failure, incomplete perfusion of important organs, acute hypoxia, and ischemia of cells and finally induce hepatic encephalopathy and hepatic necrosis [18, 19]. It has been reported that upper gastrointestinal bleeding in the patients caused mortality ranges between 3% and 14%, which is associated with rebleeding [20]. Therefore, how to effectively control bleeding is the key to improve the survival rate and reduce the mortality.

With the continuous development of clinical research, the concept of restricted fluid resuscitation has been put forward. It mainly refers to controlling the infusion speed and volume to ensure that the patient’s blood pressure is maintained at a relatively low and stable level, which finally achieves the best effect of hemostasis [21, 22]. The organ edema and organ dysfunction caused by excessive fluid infusion were reported in some clinical data [23, 24]. A small amount of fluid can avoid bleeding caused by diluting blood and filling blood vessels due to excessive amount of fluid. Restricted fluid resuscitation is associated with better outcomes, such as decreased incidence of complications and risk of death [25, 26]. In this study, the resuscitation rate of the study group was significantly higher than that of the control group. The hemostatic rate from 0h to 24h in the

Table 1: The Hb, platelet, fibrinogen, and hematocrit between the two groups.

| Group       | n     | Hb (g/L)     | Platelet (×10^9/L) | Fibrinogen (g/L) | Hematocrit (L/L) |
|-------------|-------|--------------|--------------------|-----------------|-----------------|
| Control group | 42    | 87.19 ± 9.71 | 79.94 ± 7.20       | 3.37 ± 0.57     | 41.40 ± 8.69    |
| Study group  | 42    | 96.43 ± 11.03| 88.86 ± 16.47      | 4.29 ± 0.54     | 47.04 ± 9.13    |

\( \chi^2 \quad <0.01 \quad <0.01 \quad <0.01 \quad <0.01 \)

\( P \quad <0.01 \quad <0.01 \quad <0.01 \quad <0.01 \)

Table 2: The overall response rates between the two groups.

| Group       | n     | Excellent response (n) | Good response (n) | Nonresponse (n) | Overall response rate (n (%)) |
|-------------|-------|------------------------|-------------------|----------------|-----------------------------|
| Control group | 42    | 18                     | 16                | 8              | 30 (71.43)                  |
| Study group  | 42    | 28                     | 10                | 4              | 38 (90.48)                  |

\( \chi^2 \quad — \quad — \quad — \quad — \quad 4.941 \)

\( P \quad — \quad — \quad — \quad — \quad 0.026 \)

Table 3: Resuscitation rate and infusion volume between the two groups.

| Group       | n     | Resuscitation (n) | Death (n) | Resuscitation rate (n (%)) | Infusion volume (mL) |
|-------------|-------|-------------------|-----------|---------------------------|----------------------|
| Control group | 42    | 31                 | 11        | 31 (73.81)                | 3177.27 ± 129.45     |
| Study group  | 42    | 39                 | 3         | 39 (92.86)                | 2021.50 ± 78.36      |

\( \chi^2 \quad — \quad — \quad — \quad — \quad 5.486 \)

\( P \quad — \quad — \quad — \quad — \quad 0.019 \)

\( \text{<0.001} \)

Table 4: Hemostatic rate between the two groups.

| Group       | RBC transfusion (U) | Hemostatic time (h) | Rebleeding (n (%)) | 0 h–24 h (n (%)) | 24 h–48 h (n (%)) | >48 h (n (%)) |
|-------------|---------------------|---------------------|--------------------|-----------------|-----------------|---------------|
| Control group | 3.14 ± 0.35       | 29.65 ± 5.78       | 14 (33.33%)       | 15 (35.71)      | 12 (28.57)      | 15 (35.71)    |
| Study group  | 2.55 ± 0.43       | 23.89 ± 5.84       | 5 (11.90%)        | 24 (57.14)      | 13 (30.95)      | 5 (11.90)     |

\( t/\chi^2 \quad 6.896 \quad 4.543 \quad 2.347 \quad 3.877 \quad 0.057 \quad 6.563 \)

\( P \quad <0.01 \quad <0.01 \quad <0.01 \quad <0.01 \quad <0.01 \quad <0.01 \)

Table 5: The incidence rate of complications between the two groups.

| Group       | Hepatic encephalopathy (n (%)) | Ascites (n (%)) | Spontaneous peritonitis (n (%)) | Hepatorenal syndrome (n (%)) | Hydrothorax (n (%)) | Overall incidence (n (%)) |
|-------------|--------------------------------|----------------|--------------------------------|-----------------------------|---------------------|--------------------------|
| Control group | 5 (11.90)                    | 3 (7.14)       | 2 (4.76)                      | 2 (4.76)                    | 1 (2.38)            | 13 (30.95)               |
| Study group  | 1 (2.38)                     | 1(2.38)        | 1(2.38)                       | 1(2.38)                     | 0 (0.00)            | 4 (9.52)                 |

\( \chi^2 \quad — \quad — \quad — \quad — \quad — \quad 5.974 \)

\( P \quad — \quad — \quad — \quad — \quad — \quad 0.015 \)
The data used to support the findings of this study are included within the article.

Conflicts of Interest

No potential conflicts of interest were reported by the authors.

References

[1] E. A. Tsoschatzis, J. Bosch, and A. K. Burroughs, "Liver cirrhosis," *The Lancet*, vol. 383, no. 9930, pp. 1749–1761, 2014.
[2] P. Hytiroglou, D. C. Snooper, V. Alves et al., "Beyond "cirrhosis": a proposal from the international liver pathology study group," *American Journal of Clinical Pathology*, vol. 137, no. 1, pp. 5–9, 2012.
[3] G. D’Amico, G. Garcia-Tsao, and L. Pagliaro, "Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies," *Journal of Hepatology*, vol. 44, no. 1, pp. 217–231, 2006.
[4] C. A. Mayorga and D. C. Rockey, "Clinical utility of a standardized electronic order set for the management of acute upper gastrointestinal hemorrhage in patients with cirrhosis," *Clinical Gastroenterology and Hepatology*, vol. 11, no. 10, pp. 1342–1348, 2013.
[5] M. Feinman and E. R. Haut, "Upper gastrointestinal bleeding," *Surgical Clinics of North America*, vol. 94, no. 1, pp. 43–53, 2014.
[6] E. A. Tsoschatzis, J. Bosch, and A. K. Burroughs, "New therapeutic paradigm for patients with cirrhosis," *Hepatology*, vol. 56, no. 5, pp. 1983–1992, 2012.
[7] K. Nishikawa, Y. Osawa, and K. Kimura, "Wnt/β-Catenin signaling as a potential target for the treatment of liver cirrhosis using antiﬁbrotic drugs," *International Journal of Molecular Sciences*, vol. 19, no. 10, 2018.
[8] U. Rai, T. R. Thrimawithana, C. Valery, and S. A. Young, "Therapeutic uses of somatostatin and its analogues: current view and potential applications," *Pharmacology & Therapeutics*, vol. 152, pp. 98–110, 2015.
[9] J. A. Myburgh and M. G. Mythen, "Resuscitation fluids," *New England Journal of Medicine*, vol. 369, no. 13, pp. 1243–1251, 2013.
[10] J. D. Casey, R. M. Brown, and M. W. Semler, "Resuscitation fluids," *Current Opinion in Critical Care*, vol. 24, no. 6, pp. 512–518, 2018.
[11] P. M. Cantle and B. A. Cotton, "Balanced resuscitation in trauma management," *Surgical Clinics of North America*, vol. 97, no. 5, pp. 999–1014, 2017.
[12] S. Chung, "Management of bleeding in the cirrhotic patient," *Journal of Gastroenterology and Hepatology*, vol. 17, no. 4, pp. 355–360, 2002.
[13] S. N. Sgouros, C. Bergele, N. Viazis, and A. Avgerinos, "Somatostatin and its analogues in peptic ulcer bleeding: facts and pathophysiologic aspects," *Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, vol. 38, no. 2, pp. 143–148, 2006.
[14] N. J. Costable and D. A. Greenwald, "Upper gastrointestinal bleeding," *Clinics in Geriatric Medicine*, vol. 37, no. 1, pp. 155–172, 2021.
[15] T. R. Fouad, E. Abdelsamee, W. Abdel-Razek et al., "Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: post-therapeutic outcome and prognostic indicators," *Journal of Gastroenterology and Hepatology*, vol. 34, no. 9, pp. 1604–1610, 2019.
[16] I. Khamaysi and I. M. Gralnek, "Acute upper gastrointestinal bleeding (UGIB)-initial evaluation and management," *Best Practice & Research Clinical Gastroenterology*, vol. 27, no. 5, pp. 633–638, 2013.
[17] R. A. Lirio, "Management of upper gastrointestinal bleeding in children: variceal and nonvariceal," *Gastrointestinal Endoscopy Clinics of North America*, vol. 26, no. 1, pp. 63–73, 2016.
[18] C. Antunes and I. E. Copelin, *Upper Gastrointestinal Bleeding*, StatPearls, Treasure Island, FL, USA, 2021.
[19] Y. Li, H. Li, Q. Zhu et al., "Effect of acute upper gastrointestinal bleeding manifestations at admission on the inhospital outcomes of liver cirrhosis: hematemeses versus melena without hematemeses," *European Journal of Gastroenterology and Hepatology*, vol. 31, no. 11, pp. 1334–1344, 2019.
[20] M. E. van Leerdam, "Epidemiology of acute upper gastrointestinal bleeding," *Best Practice & Research Clinical Gastroenterology*, vol. 22, no. 2, pp. 209–224, 2008.
[21] S. P. J. Macdonald, G. Keijzers, G. Keijzers et al., "Restricted fluid resuscitation in suspected sepsis associated hypotension
(REFRESH): a pilot randomised controlled trial,” *Intensive Care Medicine*, vol. 44, no. 12, pp. 2070–2078, 2018.

[22] D. Gordon and R. Spiegel, “Fluid resuscitation: history, physiology, and modern fluid resuscitation strategies,” *Emergency Medicine Clinics of North America*, vol. 38, no. 4, pp. 783–793, 2020.

[23] P. Marik and R. Bellomo, “A rational approach to fluid therapy in sepsis,” *British Journal of Anaesthesia*, vol. 116, no. 3, pp. 339–349, 2016.

[24] F. van Haren, “Personalised fluid resuscitation in the ICU: still a fluid concept?” *Critical Care*, vol. 21, no. 3, p. 313, 2017.

[25] H.-P. Xu, X.-A. Zhuo, J.-I. Yao et al., “Prognostic value of hemodynamic indices in patients with sepsis after fluid resuscitation,” *World Journal of Clinical Cases*, vol. 9, no. 13, pp. 3008–3013, 2021.

[26] R. Dong, X. Zhang, and Z. Zhao, “Ulinastatin as an adjuvant therapy to restricting volumes of resuscitation fluid strategy for patients with septic shock after initial management,” *Evidence-based Complementary and Alternative Medicine*, vol. 2021, Article ID 4231454, 9 pages, 2021.

[27] Y. Duan, J. Chen, H. Cui, and C. Zhao, “The effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding,” *American Journal of Tourism Research*, vol. 13, no. 5, pp. 5484–5490, 2021.

[28] J. L. Vincent, D. De Backer, and C. J. Wiedermann, “Fluid management in sepsis: the potential beneficial effects of albumin,” *Journal of Critical Care*, vol. 35, pp. 161–167, 2016.